三种基因在非小细胞肺癌外周血有核细胞中阳性表达的意义

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression of lung tissue-specific protein,cytokeratin 19 and calcium binding protein A4 in peripheral blood nucleated cells of patients with non-small cell lung cancer.Methods Each of 60 patients with confirmed lung benign and non-small cell lung cancer treated at Jiangxi Chest Hospital from March 2018 to December 2019 were respectively selected as study group 1 and study group 2.Then 60 healthy people of the same age who received physical examination in Jiangxi Chest Hospital during the same period were selected as the control group.The positive expression of lung tissue-specific protein,cytokeratin 19 and calcium binding protein A4 in peripheral blood nucleated cells of the three groups were detected by fluorescence quantitative PCR,and the detection results were compared.Results The levels of lung tissue-specific protein and calcium binding protein in the study 1 group were higher than those in the control group,the differences were statistically significant(P<0.05).The level of lung tissue-specific protein in the study 2 group was higher than that in the study 1 group,the difference was statistically significant(P<0.05).Three genes of expression of lung tissue-specific protein,cytokeratin 19,and calcium-binding protein A4 in peripheral blood nucleocytes in the study 2 group were higher than that in the study 1 group,the differences were statistically significant(P<0.05).Three genes of expression of lung tissue-specific protein,cytokeratin 19,and calcium-binding protein A4 in peripheral blood nucleocytes in the study 1 group were higher than that in the control group,the differences were statistically significant(P<0.05).Conclusion The positive rates of lung tissue-specific protein,cytokeratin 19 and calcium binding protein A4 in peripheral blood nucleated cells of patients with nonsmall-cell lung cancer are significantly higher than those of patients with benign lung diseases and healthy people,which could be used as an important reference for the diagnosis and treatment of NSCLC.

Key words： Non-small cell lung cancer Lung tissue specific protein Cytokeratin 19 Calcium-binding protein A4 Peripheral blood fluid Nucleated cells Positive expression

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	NONG Xue-ping

Cite this article:

NONG Xue-ping. Significance of positive expression of three genes in peripheral blood nucleated cells of non-small cell lung cancer[J]. 中国当代医药, 2021, 28(27): 120-122-126.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I27/120

[1]	吴菡，孙苏安，刘海燕，等.非小细胞肺癌EGFR 基因突变与EML4-ALK 融合基因的表达及其临床病理特征[J].实用医学杂志，2018，34（13）：2119-2122.
[2]	张坦，王艺曈，方翼.非小细胞肺癌靶向治疗药物的研究现状[J].中国临床药理学杂志，2017，33（11）：1054-1057.
[3]	贺荣芝，刘川，蔡婧，等.非小细胞肺癌EGFR、ALK、ROS1基因突变和临床病理特征分析[J].临床与实验病理学杂志，2019，35（7）：843-845.
[4]	金静思，贺巾钊，周黎明.非小细胞肺癌分子靶向治疗药物的现状及进展[J].中国肿瘤临床，2015，42（17）：881-885.
[5]	郭华，齐宗利，张海祥，等.非小细胞肺癌组织EGFR/ALK/ROS1 基因联合检测的临床意义[J].现代检验医学杂志，2018，33（6）：17-20.
[7]	郭雅琪，赵志军，师志云，等.微滴数字PCR 在非小细胞肺癌EGFR、ALK、ROS1 基因联合检测中的应用价值[J].宁夏医科大学学报，2019，41（11）：1101-1107.
[8]	白冬雨，张海萍，索文昊，等.非小细胞肺癌患者中EGFR突变、ALK 和ROS1 融合基因表达变化及其临床病理学意义[J].中国组织化学与细胞化学杂志，2019，28（1）：32-36.
[9]	崔佳音，毕力夫，苏秀兰.非小细胞肺癌表皮生长因子受体相关研究现状[J].中国医药导报，2014，11（36）：148-152.
[10]	刘颖蕾，虞永峰，陆舜.ALK 融合基因阳性非小细胞肺癌的临床研究进展[J].解放军医学杂志，2019，44（6）：527-535.
[6]	Yao Y，Peng M，Shen Q，et al.Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples[J].Thorac Cancer，2019，10（2）：193-202.
[11]	李晓锋，张冠军，汪园园，等.非小细胞肺癌EGFR、ALK和ROS1 基因联合检测及突变共存分析[J].分子诊断与治疗杂志，2018，10（6）：378-384.
[12]	王晓莉，葛晓松，刘彦魁，等.EGFR/ALK/ROS1 三联检测在非小细胞肺癌中的临床意义[J].临床与实验病理学杂志，2018，34（10）：1135-1137.
[13]	Xibin Z，Chao Z，Jiayu L，et al.Clinical features and therapeutic options in non small cell lung cancer patients with concomitant mutations of EGFR，ALK，ROS1，KRAS or BRAF[J].Cancer Medicine，2019，8（6）：2858-2866.
[14]	江薇，王懿娜.ROS1 融合基因突变在非小细胞肺癌诊断与治疗中的研究进展[J].中国肿瘤临床，2019，46（5）：257-262.
[15]	黎谢梦丹，罗凯，吴顺芳，等.华南地区非小细胞肺癌患者肿瘤组织EGFR，ALK 和ROS1 基因突变分析[J].现代检验医学杂志，2017，32（5）：16-18.
[16]	杨澜，陈勃江，李镭，等.循环肿瘤DNA 甲基化在非小细胞肺癌中的研究进展[J].中华结核和呼吸杂志，2018，41（12）：967-970.
[17]	王婷婷，李忠华，李慧峰，等.非小细胞肺癌中YAP1、SRPX2 的表达与微血管密度及预后的相关性分析[J].临床与实验病理学杂志，2020，36（3）：264-269.
[18]	William W，Ning W，Ravindra G，et al.Utilization trends and factors associated with ROS1 testing among advanced non small-cell lung cancer patients in US community practices[J].Clinical Lung Cancer，2020，6（9）：1016-1017.
[19]	王学敏，施琳，李时荣，等.纤维支气管镜刷检液基细胞学检查在肺癌诊断中的价值分析[J].重庆医学，2018，47（8）：1040-1043.
[20]	秦文婧，张双林.纤维支气管镜刷检液基薄层细胞学检查在肺癌诊断中的应用价值[J].中国实用医药，2016，11（17）：24-26.